ABIVAX (EPA:ABVX) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
ABIVAX

PRESS RELEASE

published on 10/05/2025 at 17:00, 1 month 30 days ago

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Abivax announces positive results from Phase 3 ABTECT 8-Week Induction Trials on obefazimod for ulcerative colitis treatment with no new safety concerns identified, to present further abstract on October 6

Abivax Obefazimod Ulcerative Colitis Phase 3 Trial Safety Data
BRIEF

published on 10/03/2025 at 11:59, 2 months 1 day ago

JP Morgan Chase & Co. crosses the 5% threshold at ABIVAX

Voting Rights Actions Abivax Threshold Crossing JP Morgan
BRIEF

published on 09/29/2025 at 22:10, 2 months 5 days ago

Abivax Presents New Findings on Obefazimod at UEG 2025

Abivax Obefazimod Ulcerative Colitis Phase 3 Trials UEG Meeting
PRESS RELEASE

published on 09/29/2025 at 22:05, 2 months 5 days ago

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
Abivax announces acceptance of additional late-breaking abstract from the ABTECT Phase 3 induction trials to be presented at 2025 United European Gastroenterology (UEG) Meeting

Abivax Ulcerative Colitis Gastroenterology Late-breaking Abstract ABTECT Phase 3
BRIEF

published on 09/23/2025 at 22:10, 2 months 11 days ago

Abivax: Presentation of promising data on obefazimod at the 2025 UEG congress

Abivax Obefazimod Ulcerative Colitis Phase 3 UEG Congress
PRESS RELEASE

published on 09/23/2025 at 22:05, 2 months 11 days ago

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
Abivax announces presentation of late-breaking abstract for Obefazimod at 2025 United European Gastroenterology Meeting, showcasing potential as a new therapy for ulcerative colitis

Abivax Obefazimod Ulcerative Colitis Late-breaking Abstract UEG Meeting
BRIEF

published on 09/16/2025 at 18:05, 2 months 18 days ago

ABIVAX: Distribution of Share Capital and Voting Rights

Euronext Paris Share Capital Voting Rights AMF Abivax
BRIEF

published on 09/16/2025 at 10:04, 2 months 18 days ago

JP Morgan Chase exceeds 5% threshold in ABIVAX

Capital Actions Abivax Threshold Crossing JP Morgan Chase
BRIEF

published on 09/12/2025 at 17:50, 2 months 22 days ago

Abivax Joins CAC Mid 60 and SBF 120 Indices

Euronext Paris Biotechnology Abivax SBF 120 CAC Mid 60
PRESS RELEASE

published on 09/12/2025 at 17:45, 2 months 22 days ago

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
Abivax to join CAC Mid 60 and SBF 120 Indices on Euronext Paris following annual review, enhancing visibility and investor base

Euronext Paris Abivax SBF 120 Index Inclusion CAC Mid 60

Accesswire

Published on 12/05/2025 at 02:35, 2 hours 51 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 2 hours 56 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 4 hours 26 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 21 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 26 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 1 hour 55 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 35 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 11 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 15 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 11 hours 26 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 41 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 41 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 25 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE